Take Hands for Orphan and Rare diseases
THOR therapeutics is a research-based biopharmaceutical company which delivers first-in-class therapeutics for the treatment of orphan and rare diseases by unlocking the potential of novel therapeutic targets and mechanisms.
THOR therapeutics is a research-based biopharmaceutical company, located in Daejeon (Korea), and founded in 2022. We focus on delivering first-in-class preclinical monoclonal antibodies and anti-sense oligonucleotide candidates for novel therapeutic targets.
THOR therapeutics is led by Prof. Minho Shong, Chungnam National University School of Medicine. The company was founded by Prof. Minho Shong and collaborates with Drs. Johan Auwerx, Ho Min Kim, Jin Kuk Kim and Hyon-Seung Yi.
THOR therapeutics combines the academic investigative drive to discover targets and mechanisms for innovation of research-oriented biotechnology.